Ponlimsi™ (denosumab-adet) injection
Approval Date: Mar 2026
Indicated to increase bone mass in postmenopausal women with osteoporosis at high risk of fracture, in men with osteoporosis at high risk of fracture, in men and women with glucocorticoid-induced osteoporosis with high risk of fracture, in men at high risk of fracture receiving androgen deprivation therapy to nonmetastatic cancer, and in women at high risk of fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Boncresa™ (denosumab-mobz) injection
Approval Date: Dec 2025
A biosimilar to Prolia® (denosumab), this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
Enoby™ (denosumab-qdbe) injection
Approval Date: Sep 2025
A biosimilar to Prolia®, this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
